A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ABE / average bioequivalence

[Related PubMed/MEDLINE]
Total Number of Papers: 26
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ABE  (>> Co-occurring Abbreviation)
Long Form:   average bioequivalence
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One? ---
2019 A Novel Simulation-Based Approach for Comparing the Population Against Average Bioequivalence Statistical Test for the Evaluation of Nasal Spray Products on Spray Pattern and Droplet Size Distribution Parameters. DSD, IVBE, PBE, SP
2019 Performance of the Population Bioequivalence (PBE) Statistical Test with Impactor Sized Mass Data. FDA, PBE
2019 Pharmacokinetics and bioequivalence of low-dose clopidogrel in healthy Chinese volunteers under fasted and fed conditions. RSABE
2018 Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence. TOST
2017 An approach for sample size determination of average bioequivalence based on interval estimation. ---
2017 Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. AUC
2017 Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. ANDA, AUC, Cmax, EMA, FDA, HSD, SCABE
2017 Ratio of means vs. difference of means as measures of superiority, noninferiority, and average bioequivalence. DOM, NI, RoM
10  2017 Testing for bioequivalence of highly variable drugs from TR-RT crossover designs with heterogeneous residual variances. GPQ, HV
11  2015 Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. AUC, FDA, PK
12  2014 An approximate approach to sample size determination in bioequivalence testing with multiple pharmacokinetic responses. BE, NI, NS, PK, TOST
13  2011 The effect of variability and carryover on average bioequivalence assessment: a simulation study. ---
14  2010 Comparison of average, scaled average, and population bioequivalence methods for assessment of highly variable drugs: an experience with doxifluridine in beagle dogs. BE, PBE, SABE
15  2010 [Application of multilevel models in the evaluation of bioequivalence (II).]. AUC, IBE, PBE
16  2009 Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. HVDs, SABE
17  2009 On assessing bioequivalence using genomic data with model misspecification. PK
18  2006 Comparison of models for average bioequivalence in replicated crossover designs. BE, EM, RIS
19  2003 Kullback-Leibler divergence for evaluating bioequivalence. IBE, KLD, PBE, PBE
20  2002 On statistical power for average bioequivalence testing under replicated crossover designs. FDA
21  2001 Non-traditional study designs to demonstrate average bioequivalence for highly variable drug products. AUC, CI
22  2001 Population and individual bioequivalence: lessons from real data and simulation studies. FDA
23  2000 Case studies, practical issues and observations on population and individual bioequivalence. ---
24  2000 PhRMA perspective on population and individual bioequivalence. FDA
25  2000 Some statistical considerations on the FDA draft guidance for individual bioequivalence. IBE
26  1999 Prescribability and switchability of highly variable drugs and drug products. IBE, PBE